Drug Profile
Research programme: cardiovascular disorder therapies - Cryptome Pharmaceuticals
Alternative Names: Cardiovascular disorder therapies research programme - Cryptome Pharmaceuticals; CR 001Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Cryptome Pharmaceuticals
- Class Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Thrombosis in Australia
- 22 Feb 2005 Preclinical trials in Thrombosis in Australia (unspecified route)